Patterns of increasing beta-agonist use and the risk of fatal or near-fatal asthma

The association between the use of inhaled beta-agonists by metered-dose inhaler and the risk of fatal or near-fatal asthma has been demonstrated. It shows that asthmatics who use one canister of beta-agonist per month more than the number used by other similar asthmatics have twice the risk of fatal or near-fatal asthma. The present investigation assesses the magnitude of this excess risk when an asthmatic increases his/her own monthly use of inhaled beta-agonists over time. From a previous nested case-control study of 129 deaths and near-deaths from asthma (cases) and 655 controls from a cohort of 12,301 asthmatics, the subset using at least 12 inhalers during the 12 month study period was identified (97 cases and 258 controls). A profile score, ranging 0-11, was formed to quantify the patterns of beta-agonist use over time for each subject, covering the entire spectrum extending from decreasing to increasing use. The relative risk was 15.2 (95% confidence interval (CI) 2.4-96.2) per unit increase of the profile score in subjects with a pattern of increasing beta-agonist use (profile score of 6.5 or more), but this relative risk was only 1.5 (95% CI 0.8-2.6) per unit when the profile score was less than 6.5 (non-increasing use). This relative risk was independent of the risk associated with the total quantity of beta-agonist use in the 12 month period, which remained around 1.6 (95% CI 1.3-2.0) per inhaler per month.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				D. R. Taylor The {beta}-Agonist Saga and Its Clinical Relevance: On and On It Goes Am. J. Respir. Crit. Care Med., June 1, 2009; 179(11): 976 - 978. [Abstract] [Full Text] [PDF]

				M. O. Turner Inhaled Corticosteroids and Pneumonia in COPD: An Association Looking for Evidence Am. J. Respir. Crit. Care Med., March 1, 2008; 177(5): 555 - 556. [Full Text] [PDF]

				E. D. Bateman, S. S. Hurd, P. J. Barnes, J. Bousquet, J. M. Drazen, M. FitzGerald, P. Gibson, K. Ohta, P. O'Byrne, S. E. Pedersen, et al. Global strategy for asthma management and prevention: GINA executive summary Eur. Respir. J., January 1, 2008; 31(1): 143 - 178. [Abstract] [Full Text] [PDF]

				E. A. Wammes-van der Heijden, H. Rahimtoola, H.G.M. Leufkens, C. C. Tijssen, and A. C.G. Egberts Risk of ischemic complications related to the intensity of triptan and ergotamine use. Neurology, October 10, 2006; 67(7): 1128 - 1134. [Abstract] [Full Text] [PDF]

				S. R. Salpeter, N. S. Buckley, T. M. Ormiston, and E. E. Salpeter Meta-Analysis: Effect of Long-Acting {beta}-Agonists on Severe Asthma Exacerbations and Asthma-Related Deaths Ann Intern Med, June 20, 2006; 144(12): 904 - 912. [Abstract] [Full Text] [PDF]

				A. Senthilselvan, J. A. Lawson, D. C. Rennie, and J. A. Dosman Regular Use of Corticosteroids and Low Use of Short-Acting {beta}2-Agonists Can Reduce Asthma Hospitalization Chest, April 1, 2005; 127(4): 1242 - 1251. [Abstract] [Full Text] [PDF]

				D. Kaya, I. Barutcu, A. M. Esen, E. Onrat, A. Orman, and M. Unlu Comparison of the effects of ipratropium bromide and salbutamol on autonomic heart rate control Europace, January 1, 2004; 6(6): 602 - 607. [Abstract] [Full Text] [PDF]

				L. D. Lynd, D. P. Guh, P. D. Pare, and A. H. Anis Patterns of Inhaled Asthma Medication Use: A 3-Year Longitudinal Analysis of Prescription Claims Data From British Columbia, Canada Chest, December 1, 2002; 122(6): 1973 - 1981. [Abstract] [Full Text] [PDF]

				H. W. Kelly The Management of Acute Severe Asthma Journal of Pharmacy Practice, April 1, 2001; 14(2): 91 - 107. [Abstract] [PDF]

				R. J. Adams, A. Fuhlbrigge, J. A. Finkelstein, P. Lozano, J. M. Livingston, K. B. Weiss, and S. T. Weiss Use of Inhaled Anti-inflammatory Medication in Children With Asthma in Managed Care Settings Arch Pediatr Adolesc Med, April 1, 2001; 155(4): 501 - 507. [Abstract] [Full Text] [PDF]

				R. J. Adams, A. Fuhlbrigge, J. A. Finkelstein, P. Lozano, J. M. Livingston, K. B. Weiss, and S. T. Weiss Impact of Inhaled Antiinflammatory Therapy on Hospitalization and Emergency Department Visits for Children With Asthma Pediatrics, April 1, 2001; 107(4): 706 - 711. [Abstract] [Full Text] [PDF]

				S. F. LANES, L. L. LANZA, and C. E. WENTWORTH III Risk of Emergency Care, Hospitalization, and ICU Stays for Acute Asthma among Recipients of Salmeterol Am. J. Respir. Crit. Care Med., September 1, 1998; 158(3): 857 - 861. [Abstract] [Full Text] [PDF]

				D R. Taylor, G I. Town, G P. Herbison, D. Boothman-Burrell, E. M Flannery, B. Hancox, E. Harré, K. Laubscher, V. Linscott, C. M Ramsay, et al. Asthma control during long term treatment with regular inhaled salbutamol and salmeterol Thorax, September 1, 1998; 53(9): 744 - 752. [Abstract] [Full Text]

				M. O. TURNER, K. NOERTJOJO, S. VEDAL, T. BAI, S. CRUMP, and J. MARK FITZGERALD Risk Factors for Near-fatal Asthma . A Case-Control Study in Hospitalized Patients with Asthma Am. J. Respir. Crit. Care Med., June 1, 1998; 157(6): 1804 - 1809. [Abstract] [Full Text] [PDF]

				J. G. Donahue, S. T. Weiss, J. M. Livingston, M. A. Goetsch, D. K. Greineder, and R. Platt Inhaled Steroids and the Risk of Hospitalization for Asthma JAMA, March 19, 1997; 277(11): 887 - 891. [Abstract] [PDF]

				S. Suissa, P. Ernst, D. Zahger, J. M. Drazen, E. Israel, and The National Heart, Lung, and Blood Institute's As Albuterol in Mild Asthma N. Engl. J. Med., March 6, 1997; 336(10): 729 - 730. [Full Text]

				H. S. Nelson {beta}-Adrenergic Bronchodilators N. Engl. J. Med., August 24, 1995; 333(8): 499 - 507. [Full Text] [PDF]